Oral IL-23 Receptor Blocker Icotrokinra Significantly Improves Skin Clearance in Plaque Psoriasis: NEJM

Published On 2025-11-19 15:00 GMT | Update On 2025-11-19 15:00 GMT

A study published in The New England Journal of Medicine has reported that the oral peptide icotrokinra, a selective interleukin-23 (IL-23) receptor blocker, achieved significantly greater skin clearance at 16 weeks compared with placebo in adults and adolescents with moderate-to-severe plaque psoriasis. This advancement marks a key step toward developing an oral biologic alternative for psoriasis management, offering a more convenient treatment option than injectable therapies. The authors note that ongoing research will be important to determine the long-term safety and durability of treatment response.

The trial evaluated the efficacy and safety of icotrokinra in a randomized, placebo-controlled setting, with participants receiving oral doses of the peptide over 16 weeks. The therapy works by selectively blocking the IL-23 receptor, a critical signaling pathway involved in psoriasis pathogenesis and chronic skin inflammation. Participants treated with icotrokinra demonstrated marked improvements in skin lesion clearance and overall disease severity scores, underscoring the clinical potential of targeting IL-23 with an oral approach. The safety profile was generally consistent with expectations, showing no new concerning signals during the study period.

These results position icotrokinra as a promising next-generation therapeutic option for patients seeking non-injectable alternatives for psoriasis treatment. By offering an oral route with biologic-like efficacy, this drug could simplify long-term disease management and improve patient adherence. Future studies will focus on sustained efficacy, relapse prevention, and safety over extended treatment durations, as well as its potential in other IL-23–driven inflammatory conditions.

Keywords: plaque psoriasis, icotrokinra, interleukin-23 receptor, IL-23 blockade, oral therapy, biologic alternative, psoriasis treatment, skin clearance, New England Journal of Medicine.

Reference :

Reich, K., Blauvelt, A., Griffiths, C. E. M., Lebwohl, M., Langley, R. G., Strober, B. E., et al. (2025). Oral IL-23 receptor blocker icotrokinra in moderate-to-severe plaque psoriasis. The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2504187

Article Source : The New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Book Released on 'Psoriasis: Evidence-Based Diagnosis and Treatment' Offering Updated Comprehensive Clinical Insights for Clinicians

2025-11-13 06:48 GMT

Oral IL-23 Receptor Blocker Icotrokinra Significantly Improves Skin Clearance in Plaque Psoriasis: NEJM

Similar News

Topical Timolol Found Safe and Well-Tolerated for Infantile Hemangioma: Study

Combined IPL and Radiofrequency Therapy Improves Outcomes in Hidradenitis Suppurativa: Study

Increased disease burden observed in hidradenitis suppurativa patients with arthritis: Study

Seborrheic Dermatitis Linked to Epithelial Barrier Disorders Across Multiple Organs: JAMA

COVID-19 vaccination linked to reduced infections in children with eczema: Study

New study gives people with eczema freedom to choose how often to bathe

Book Released on 'Psoriasis: Evidence-Based Diagnosis and Treatment' Offering Updated Comprehensive Clinical Insights for Clinicians